Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p16AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qRT-PCR , Luciferase reporter assay , Western blot etc. |
| Sample | human HCC cell lines( MHCC97 and Li-7) ,non-tumourigenic liver cell line THLE-3 |
| Expression Pattern | up-regulated |
| Function Description | ANRIL was highly expressed in MHCC97 and Li-7 cells when compared to THLE-3 cells.ANRIL overexpression promoted cell viability, migration, invasion and suppressed apoptosis of MHCC97 and Li-7 cells.ANRIL negatively regulated miR-144, and oncogenic effects of ANRIL were attenuated when miR-144 was overexpressed.PBX3 was a direct target of miR-144. miR-144 overexpression blocked PI3K/AKT and JAK/STAT signalling pathways via targeting PBX3.ANRIL promoted hepatocellular carcinoma cells growth, migration and invasion. |
| Pubmed ID | 31609763 |
| Year | 2019 |
| Title | LncRNA ANRIL Promotes Cell Growth, Migration and Invasion of Hepatocellular Carcinoma Cells via Sponging miR-144 |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |